Allergy & Immunology

Dupilumab’s Impact on Mucus Plug Dynamics and Radiodensity in Moderate to Severe Asthma: A CT Imaging Perspective

By MedXY 09/22/2026

Dupilumab treatment in moderate to severe asthma significantly reduces mucus plug burden, resolves existing plugs, limits new plug formation, and decreases plug radiodensity on CT scans, correlating with improved lung function and ventilation.

Allergy & Immunology Gastroenterology news

Unveiling the TL1A-LTα1β2/IL-22 Axis: A New Therapeutic Target in Crohn’s Disease with Perianal Fistulising Disease

By MedXY 09/19/2026

This study reveals that TL1A-activated CD4+ T cells drive distinct cellular and molecular changes in the rectal mucosa of Crohn's disease patients with perianal fistulising disease (PFD), highlighting a novel TL1A-LTα1β2/IL-22 axis independent of TNF signaling, with important therapeutic implications.

Allergy & Immunology news Respiratory

Rademikibart and Eosinophil Counts in Moderate-to-Severe Asthma: Insights from a Phase 2b Randomized Trial

By MedXY 09/18/2026

This article reviews exploratory analyses from a phase 2b trial examining eosinophil count changes in adults with uncontrolled moderate-to-severe asthma treated with the IL-4Rα inhibitor rademikibart, indicating a low risk of treatment-emergent hypereosinophilia.

Allergy & Immunology news Respiratory

Tezepelumab Demonstrates Robust Efficacy and Safety Across Diverse Severe Asthma Phenotypes: Insights from the Phase 4 PASSAGE Study

By MedXY 09/12/2026

The PASSAGE phase 4 study reveals tezepelumab significantly reduces exacerbation rates and improves lung function and quality of life in a broad US severe asthma population, including underrepresented groups and varied phenotypes.

Allergy & Immunology Diabetes & Endocrinology news

Unraveling Genetic Pathways in Type 1 Diabetes: Distinct HLA-DR3 and DR4 Effects on Disease Progression

By MedXY 09/05/2026

This study reveals that genetic risk factors and immune pathways differ significantly between type 1 diabetes patients stratified by HLA-DR3 and HLA-DR4 status, providing insights into disease heterogeneity and personalized risk mechanisms.

Allergy & Immunology Hematology-Oncology news

Divergent Roles of IL-12p40 and IL-18 in Severe Fibrosing Chronic Graft-versus-Host Disease: Implications for Immunity and Post-Transplant Outcomes

By MedXY 08/28/2026

This study reveals distinct clinical associations of IL-12p40 and IL-18 in severe fibrosing chronic graft-versus-host disease, highlighting their differing impacts on relapse risk, survival, and immune responses post-allogeneic stem cell transplantation.

Allergy & Immunology news Ophthalmology

Immune-Mediated Disorders and Central Serous Chorioretinopathy: Clinical Insights from the MICRoN Report 21

By MedXY 08/26/2026

This study reveals that central serous chorioretinopathy (CSCR) in patients with immune-mediated disorders exhibits distinct clinical and imaging features, with immune-mediated status linked to poorer visual outcomes and higher recurrence, influenced by corticosteroid exposure.

Allergy & Immunology Cardiology news

Unveiling Hidden Immune Signatures in Cardiovascular Disease Through Single-Cell Multi-Omics

By MedXY 08/21/2026

Single-cell multi-omics profiling reveals novel immune signatures linked to coronary artery disease and cardiovascular outcomes, independent of traditional inflammatory markers, offering new avenues for risk stratification and personalized therapy.

Allergy & Immunology Clinical Updates news Respiratory

Exploring the Role of Autoimmune Conditions in Acute Interstitial Pneumonia: Clinical Outcomes and Implications

By MedXY 08/20/2026

Autoimmune conditions in acute interstitial pneumonia (AIP) are associated with reduced 90-day mortality and better discharge outcomes, indicating distinct clinical trajectories and opportunities for tailored care.

Allergy & Immunology Clinical Updates Dermatology news

Upadacitinib for Severe Alopecia Areata in Adults and Adolescents: Evidence from Two Phase 3 UP-AA Randomized Clinical Trials

By MedXY 08/17/2026

Two large phase 3 trials demonstrated that upadacitinib significantly improves hair regrowth and quality of life in severe alopecia areata among adolescents and adults, with a consistent and manageable safety profile.

Allergy & Immunology Neurology news

Inebilizumab Significantly Reduces Exacerbations and Need for Rescue Therapy in Generalized Myasthenia Gravis: Insights from the Phase 3 MINT Trial

By MedXY 08/14/2026

The MINT trial demonstrates that inebilizumab markedly lowers exacerbation rates and rescue therapy use in AChR+ and MuSK+ generalized myasthenia gravis patients undergoing corticosteroid tapering.

Allergy & Immunology Dermatology news

Early Prediction of Dupilumab Efficacy in Facial Atopic Dermatitis via Reflectance Confocal Microscopy and Deep Learning

By MedXY 08/12/2026

Reflectance confocal microscopy features at week 4 post-dupilumab treatment, combined with deep learning analysis, enable non-invasive prediction of therapeutic response in facial atopic dermatitis patients.

Allergy & Immunology Critical Care Emergency Medicine news

Evaluating the Impact of a Prehospital 1-Hour Resuscitation Bundle on Septic Shock Mortality: Insights from the SAMU Save Sepsis Study

By MedXY 08/11/2026

A multicenter randomized trial found that initiating a 1-hour resuscitation bundle including early antibiotics, fluids, vasopressors, and hydrocortisone in the prehospital setting did not significantly reduce 28-day mortality in adults with septic shock.

Allergy & Immunology Critical Care news

Functional Impairment of Natural Killer Cells After Severe Trauma: Phenotypic Shifts and Loss of Activating Receptors

By MedXY 08/11/2026

Severe trauma induces maturation and cytotoxic phenotypes in NK cells but paradoxically decreases expression of activating receptors critical for immune defense, revealing a mechanism underlying posttrauma immune dysregulation and vulnerability to infection.

Allergy & Immunology Critical Care news

Dynamic Alterations in Natural Killer Cell Phenotype and Activating Receptor Expression Following Trauma: Insights into Immune Dysregulation

By MedXY 08/11/2026

Severe trauma induces phenotypic maturation of natural killer cells but leads to a loss of key activating receptors, potentially driving posttraumatic immune dysfunction and increased infection risk.

Allergy & Immunology news Respiratory

Decoding the Immune Landscape of COPD: Single-Cell RNA Sequencing Reveals Profibrotic Macrophage and Monocyte Niches Driving Disease Progression

By MedXY 08/04/2026

This study uses single-cell RNA sequencing of bronchoalveolar lavage cells to reveal immune dysregulation in COPD, highlighting profibrotic macrophages and monocytes as key players in airway remodeling and gas exchange impairment.

Allergy & Immunology Hematology-Oncology news

Secondary Autoimmune and Inflammatory Diseases Post-Allogeneic Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors, and Clinical Outcomes from the EBMT Registry

By MedXY 08/02/2026

This retrospective EBMT study identifies secondary autoimmune and inflammatory diseases as rare but significant complications following allo-HSCT, highlighting their incidence, risk factors, and impact on patient survival, calling for improved diagnostic and management strategies.

Allergy & Immunology Dermatology news

CD19 CAR T-cell Therapy Without Lymphodepletion Shows Promise in Pemphigus Vulgaris: Insights from the RESET-PV Trial

By MedXY 08/02/2026

Early results from the RESET-PV trial indicate that CD19 CAR T-cell therapy without lymphodepleting preconditioning is feasible and safe for pemphigus vulgaris, offering significant clinical improvement and durable B-cell depletion.

Allergy & Immunology news Respiratory

Unveiling the Roles of Mast Cells and Endothelial Cells in IL-33/ST2 Pathway Dysregulation in COPD Lungs

By MedXY 07/20/2026

This study elucidates distinct cellular expression patterns of IL-33 and its receptor variants ST2L and sST2 in COPD lungs, highlighting mast cells and endothelial cells as key mediators in the distal lung immune response.

Allergy & Immunology Neurology news

Interleukin 6 Receptor Blockade: A Promising Strategy for Relapse Prevention in MOG Antibody-Associated Disease

By MedXY 07/16/2026

IL-6 receptor blockade significantly reduces relapse rates in MOG antibody-associated disease, showing comparable efficacy to high-dose IVIG with a favorable safety profile, supporting its role in relapse prevention.